Research programme: GPCR modulators - Heptares Therapeutics/New York University School of Medicine

Drug Profile

Research programme: GPCR modulators - Heptares Therapeutics/New York University School of Medicine

Alternative Names: G protein-coupled receptor modulators - Heptares Therapeutics/New York University School of Medicine

Latest Information Update: 30 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics; New York University School of Medicine
  • Class Antineoplastics
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Glioblastoma

Most Recent Events

  • 28 Jun 2017 Heptares Therapeutics enters into a research and discovery collaboration under its ORBIT initiative with New York University School of Medicine for Cancer, including glioblastoma
  • 28 Jun 2017 Early research in Glioblastoma in USA, United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top